CEO Of Tasly Pharmaceuticals Inc. Gives Keynote At ACC18 On Herbal Therapy For Heart Disease
On March 12, 2018, Dr. Henry Sun, PhD, and CEO/President of Tasly Pharmaceuticals, Inc. took the stage at this year’s American College of Cardiology (ACC) conference as a keynote speaker to present on a new topic. He spoke about the future of herbal therapies to support heart disease treatments, citing a recent completion of a clinical trial of an herbal combination called T89.
The American College of Cardiology 2018 Conference
Orlando, FL, hosted this year’s 67th Annual ACC conference. The conference includes scientific sessions and an exposition hall. Speakers and presenters came from more than 137 countries around the world with more than 18,000 attendees. The expo hall gave attendees an opportunity to meet with 280 exhibitors in the fields of medical devices and equipment, pharmaceuticals, imaging, diagnostics, health-related IT and continuing medical education.
Professional attendees had the opportunity to earn continuing education credits. They also had the opportunity to learn about the lastest state-of-art scientific research and studies like the one Dr. Sun shared.
An FDA Regulated Study of a Botanical Drug
The FDA regulated, multi-country, double-blind randomized and placebo-controlled study explored the effect of T89, a three-herb combination, on patients with chronic stable angina. The three herbs in T89 are Danshen, Sanqi (notoginseng), and Borneol. The study sought to demonstrate the safety and effectiveness of T89 as an add-on therapy to traditional anti-anginal drugs (beta-blockers, calcium channel blockers and nitrates) alone.
At the end of the study, patients taking T89 experienced significant reductions in frequency of angina and a need for nitrates. No adverse events were reported were comparable to those experienced by those taking the placebo. The study authors concluded:
- The herbal combination of Danshen, Sanqi and Borneol offers angina patients an effective therapy for their condition.
- Matched the benefits observed in 22 years of clinical use worldwide.
- Met all necessary safety parameters.
In their discussion, the study authors noted T89 acts differently than traditional anti-anginal drugs. Rather that simply targeting the coronary artery, the three herbs work together to improve microcirculation, blood flow and energy metabolism. This supports the entire cardiovascular system.
The researchers also noted T89 did not interfere with drugs, although any time an herbal product will be taken with current medications, it should be done under the supervision of a doctor.
About Tasly Pharmaceuticals, Inc.
Tasly Pharmaceuticals Inc. promotes a holistic approach to medicine through the application of Innovative Chinese Medicine (ICM). Tasly applies cutting-edge research and technology combined with clinical evidence to develop quality-controlled herbal medicines based on the theory of synergism from Traditional Chinese Herbal Medicine to provide safe, natural medicines, giving patients more choices of treatment.